Price Controls Remain A Barrier To Robust and Reciprocal U.S.-India Economic Relationship
Without meaningful changes to regulatory policies in India, price controls that impact medical devices, pharmaceutical products, among other sectors, will remain costly barriers to trade and investment for U.S. companies in India. In comments made this year to USTR, AFTI described particular concern with price controls in India. To this ...
Continue Reading →